リフトバレー熱（RVF）ワクチンの世界市場：タイプ別、用途別、地域別、予測

リフトバレー熱（RVF）ワクチンの市場規模と予測

リフトバレー熱（RVF）ワクチン市場は近年急成長を遂げており、2026年から2032年にかけて大きく成長すると予測されています。

リフトバレー熱（RVF）は、ブニヤウイルス科のウイルスによって引き起こされます。ウイルスは主に蚊に刺されたり、感染した動物や組織と接触することで感染します。RVFVはヒトに発熱、頭痛、筋肉や関節の不快感など様々な症状を引き起こしますが、重症の場合は出血熱や脳炎を引き起こします。このウイルスは妊娠中の家畜に流産を引き起こし、幼若な家畜にはかなりの死亡率をもたらします。

リフトバレー熱（RVF）は人獣共通感染症のウイルス性疾患で、主に動物が罹患しますが、時に人に感染し、重篤な罹患率と死亡率を引き起こすことがあります。RVFの発生を抑え、その伝播を防ぐためにはワクチン接種が不可欠です。RVFワクチンは弱毒生ワクチン、不活化ワクチン、遺伝子組換えワクチンなど様々な形で開発されています。スミスバーンワクチン株のような弱毒生ワクチンは、伝統的に流行地域で利用されており、効果的な動物防御を提供しています。

しかし、安全性や再び病原性を持つようになる可能性から、より安全な代替ワクチンの開発が進められてきました。ホルマリン不活化ウイルスから作られた不活化ワクチンは、RVF予防のためのもう一つの選択肢ですが、効果を得るためには何度も接種する必要があります。

リフトバレー熱（RVF）ワクチンの世界市場力学

リフトバレー熱（RVF）ワクチンの世界市場を形成している主な市場力学は以下の通り：

主な市場促進要因

RVFの発生：特にアフリカと中東の流行地域におけるRVFの発生は、RVFワクチン市場の主要促進要因です。このような発生は、病気の蔓延を抑えるための予防接種を含む効果的な予防対策の必要性を強調しています。

公衆衛生への影響：RVFは動物およびヒトの双方に重篤な罹患率と死亡率を引き起こす可能性があり、世界の公衆衛生への影響が懸念されています。政府や保健機関は、RVFの発生が公衆衛生や動物集団に与える影響を軽減するため、ワクチン接種の取り組みを優先しています。

気候変動と生態学的変数：降雨量の増加や洪水などの生態学的変化は、RVF媒介蚊の増殖やウイルスの拡散を助長する可能性があります。このような環境変化はRVF発生の危険性を高め、予防戦略としてのワクチンの需要を押し上げます。

家畜生産の増加：家畜は病気に対して非常に敏感であるため、世界の畜産セクターが成長するにつれ、RVFワクチン接種の需要も増加します。家畜の数が増え、農作業が強化されるにつれ、家畜を保護し、食料安全保障を確保するための効果的なワクチンの需要が高まっています。

主な課題

ワクチンの有効性と安全性：RVFワクチンの有効性と安全性を確保することは大きな課題です。ワクチン候補の中には、有効性が低かったり、特定の動物種や個体群に悪影響を及ぼすものもあります。有効性と安全性のバランスをとることは、規制当局の承認と一般大衆の受容性を達成するために依然として重要です。

ワクチン開発と製造のコスト：ワクチンの研究開発には、前臨床試験、臨床試験、規制当局の承認などが含まれ、時間と費用がかかります。さらに、大規模なワクチン製造には製造施設やインフラへの大規模な投資が必要であり、ワクチン開発企業にとってはコスト高となる可能性があります。

サーベイランスと早期発見：RVFの発生を早期に発見することは、ワクチン接種やその他の管理努力を適時に実施するために極めて重要です。しかし、多くの地域では、監視システムが不十分であったり、資金不足であったりするため、アウトブレイクの認識や対応が遅れ、ワクチン接種キャンペーンの効果が制限される可能性があります。

被災地における資源の制約：RVFが流行しやすい地域の多くは、インフラが不十分で、医療サービスも最低限しかないです。そのため、ワクチン投与や疾病サーベイランスに支障をきたす可能性があります。

主要動向：

ワクチン技術の進歩：RVFワクチン市場は、組み換えワクチンや新規ワクチン送達システムの開発などの技術革新によって牽引されています。こうした技術革新により、ワクチンの有効性、安全性、投与の利便性が向上し、次世代RVFワクチンの開発につながる可能性があります。

マルチセクターコラボレーション：政府、学術機関、製薬会社間の官民パートナーシップは、ワクチン開発努力を加速させる。

新興国と投資：RVFが公衆衛生上および経済的に重大な危険性を持つことが認識されるにつれ、RVFワクチンの研究開発への投資が、特に新興国を中心に増加しています。政府、国際機関、民間セクターのパートナーは、効果的な疾病予防戦略に対する需要の高まりに応えるため、RVFワクチンの開発に投資しています。

規制の調和と迅速な承認プロセス：RVFワクチンの規制基準の標準化と承認プロセスの合理化に向けた取り組みにより、革新的なワクチン候補の迅速な市場参入と展開が可能になってきています。特にRVFが深刻な危険性をはらんでいる地域では、RVFワクチン接種の審査とライセンシングを迅速化するため、規制当局の連携が進んでいます。

目次

第1章 リフトバレー熱（RVF）ワクチンの世界市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 リフトバレー熱（RVF）ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 リフトバレー熱（RVF）ワクチンの世界市場：タイプ別

• 概要
• 不活化ワクチン
• 生ワクチン

第6章 リフトバレー熱（RVF）ワクチンの世界市場：用途別

• 概要
• 牛
• 山羊
• 人
• 羊
• その他

第7章 リフトバレー熱（RVF）ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東

第8章 世界のリフトバレー熱（RVF）ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Veterinary Serum and Vaccine Research Institute
• Onderstepoort Biological Products SOC Ltd
• Medgene Labs

第10章 付録

• 関連調査

Rift Valley Fever Vaccines Market Size And Forecast

The Rift Valley Fever Vaccines Market has grown at a rapid pace in recent years, and it is expected to rise significantly between 2026 and 2032.

Rift Valley Fever (RVFV) is caused by a virus from the Bunyaviridae family. The virus spreads mostly through mosquito bites or contact with infected animals or tissues. RVFV can produce a variety of symptoms in humans, including fever, headache, and muscle and joint discomfort; in severe cases, it can result in hemorrhagic fever or encephalitis. The virus can lead to abortion in pregnant livestock and significant mortality rates in young animals.

Rift Valley Fever (RVF) is a zoonotic viral disease that mostly affects animals but can occasionally infect people, causing severe morbidity and mortality. Vaccination is essential for controlling RVF outbreaks and preventing their propagation. RVF vaccines have been created in many forms including live attenuated, inactivated, and recombinant. Live attenuated vaccines, such as the Smithburn vaccine strain, have traditionally been utilized in endemic areas and provide effective animal protection.

However, safety and the possibility of reversion to virulence have prompted the creation of safer alternatives. Inactivated vaccines made from formalin-inactivated viruses offer another alternative for RVF protection, although they require many doses to be effective.

Global Rift Valley Fever Vaccines Market Dynamics

The key market dynamics that are shaping the global rift valley fever vaccines market include:

Key Market Drivers:

RVF Outbreaks: The incidence of RVF outbreaks particularly in endemic areas of Africa and the Middle East is a major driver of the RVF vaccine market. These outbreaks underscore the critical need for effective preventative measures, including immunization to curb the disease's spread.

Impacts on Public Health: RVF has the potential to cause severe morbidity and mortality in both animals and humans, raising global public health implications. Governments and health organizations prioritize vaccination initiatives to reduce the impact of RVF outbreaks on public health and animal populations.

Climate Change and Ecological Variables: The ecological changes such as increasing rainfall and flooding, can foster the growth of RVF vectors (mosquitoes) and the spread of the virus. These environmental changes increase the danger of RVF outbreaks, pushing up the demand for vaccines as a preventive strategy.

Increased Livestock Production: As the global livestock sector grows, so does the demand for RVF vaccinations, as cattle are very sensitive to disease. With growing livestock numbers and intensified farming practices, there is an increased demand for effective vaccines to protect animals and assure food security.

Key Challenges:

Vaccine Efficacy and Safety: Ensuring the efficacy and safety of RVF vaccines presents a considerable challenge. Some vaccination candidates may have poor efficacy or cause adverse effects in specific animal species or populations. Balancing efficacy and safety remains critical for achieving regulatory approval and public acceptability.

Cost of Vaccine Development and Production: The vaccine research and development process, which includes preclinical studies, clinical trials, and regulatory clearances, is time-consuming and expensive. Furthermore, large-scale vaccine production necessitates major investments in manufacturing facilities and infrastructure, which can be costly for vaccine developers.

Surveillance and Early Detection: Early detection of RVF outbreaks is critical for the timely implementation of vaccination and other management efforts. However, in many locations surveillance systems may be insufficient or underfunded, resulting in delays in recognizing and responding to outbreaks, limiting the effectiveness of vaccination campaigns.

Resource Constraints in Affected Regions: Many regions prone to RVF epidemics have inadequate infrastructure and minimal healthcare services. This could hinder vaccine administration and disease surveillance efforts.

Key Trends:

Advancements in Vaccine Technology: The RVF vaccines market is being driven by technological innovations such as the development of recombinant vaccines and novel vaccine delivery systems. These improvements present chances for improving vaccine efficacy, safety, and convenience of administration, potentially leading to the development of next-generation RVF vaccines.

Multi-sector Collaborations: Public-private partnerships between governments, academic institutions, and pharmaceutical companies accelerate vaccine development efforts.

Emerging Nations and Investment: The growing acknowledgment of RVF as a significant public health and economic hazard is driving up investment in RVF vaccine research and development, particularly in emerging nations. Governments, international organizations, and private sector partners are investing in the development of RVF vaccines to meet the growing demand for effective disease prevention strategies.

Regulatory Harmonization and Accelerated Approval Processes: Efforts to standardize regulatory standards and streamline approval processes for RVF vaccines are allowing for faster market entry and deployment of innovative vaccine candidates. Regulatory agencies are increasingly working together to expedite the review and licensing of RVF vaccinations, particularly in areas where the illness is a severe danger.

Global Rift Valley Fever Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the global rift valley fever vaccines market:

North America:

In North America, the rift valley fever (RVF) vaccine market is distinguished by a proactive approach to disease prevention and management. While RVF is not endemic in North America, the region bears the risk of imported cases as a result of worldwide travel and trade.

As a result, public health officials, veterinary organizations, and livestock producers are increasingly aware of the necessity of being prepared for and monitoring emerging infectious illnesses such as RVF.

In recent years, efforts have been undertaken to improve surveillance systems and tighten biosecurity measures to reduce the danger of RVF introduction and dissemination. Although RVF vaccines are not extensively utilized in North America, research and development initiatives are continuing to create viable vaccines that could be used in the event of an outbreak.

Additionally, interactions between government agencies, academic institutions, and commercial sector stakeholders help to promote RVF vaccine development and readiness activities in the region. The North American RVF vaccines market is driven by a proactive approach to developing infectious illnesses, as well as a commitment to protecting public health and animal agriculture from future RVF threats.

Europe:

The Rift Valley Fever (RVF) vaccines market in Europe is expanding rapidly, owing to a number of factors. While RVF is not endemic in Europe, the region is at risk from the global spread of infectious illnesses caused by factors such as international travel and trade, climate change, and animal population mobility. As a result, public health officials and veterinary agencies are increasingly emphasizing the necessity of preparedness and surveillance for new diseases such as RVF.

This increased awareness has resulted in more funding for RVF vaccine research and development. Furthermore, advances in vaccination technology and the emergence of novel vaccine candidates have helped to expand the RVF vaccines market in Europe. Collaboration among government agencies, academic institutions, and commercial sector partners is accelerating innovation and easing the development of effective RVF vaccines.

Furthermore, regulatory alignment and streamlined approval processes are speeding up the entry of novel vaccine medicines into the market. Overall, the European area offers a promising growth opportunity for the RVF vaccines market, with a growing emphasis on disease preventive and control methods to reduce the potential effect of RVF outbreaks.

Asia Pacific:

The Asia Pacific Rift Valley Fever (RVF) vaccine market is expanding rapidly, owing to reasons such as increased animal output, increased knowledge of zoonotic illnesses, and expanded disease surveillance and control efforts. While RVF outbreaks have historically been more common in Africa and the Middle East, the Asia Pacific region is not immune to the threat of RVF, thanks to globalization, climate change, and animal and human migration.

As a result, there is a rising realization of the need to improve RVF readiness and response mechanisms throughout the region. Governments, veterinary agencies, and international organizations are all actively involved in surveillance, risk assessment, and capacity-building activities to reduce the risk of RVF introduction and distribution. Additionally, research and development efforts are underway to provide effective RVF vaccines that are tailored to the regional setting.

Global Rift Valley Fever Vaccines Market: Segmentation Analysis

The Rift Valley Fever Vaccines Market is segmented on the basis of Type, Application, And Geography.

Rift Valley Fever Vaccines Market, By Type

• Inactivated
• Live

Based on Type, the market is divided into Inactivated and Live. The inactivated vaccines category presently dominates, owing to advances in vaccination technology and a focus on safety. Inactivated vaccines are highly safe since they do not contain live viruses making them appropriate for use in a variety of animal species.

Rift Valley Fever Vaccines Market, By Application

• Cattle
• Goats
• People
• Sheep
• Other

Based on Application, the market is segmented into Cattle, Goats, People, and Sheep. The dominance and growth of vaccine usage in the Rift Valley Fever (RVF) vaccines market differs by species. The market for RVF vaccines is now dominated by vaccines for cattle and sheep, indicating the enormous economic impact of RVF on these livestock species.

Key Players

The "Global Rift Valley Fever Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Veterinary Serum and Vaccine Research Institute, Onderstepoort Biological Products SOC Ltd., and Medgene Labs. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Rift Valley Fever Vaccines Market Recent Developments
• In October 2023, The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its collaboration with Wageningen Bioveterinary Research (WBVR) to move WBVR's vaccine candidate against Rift Valley fever (RVF) forward in a multi-site Phase I/IIa clinical trial.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL RIFT VALLEY FEVER VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL RIFT VALLEY FEVER VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL RIFT VALLEY FEVER VACCINES MARKET, BY TYPE

• 5.1 Overview
• 5.2 Inactivated
• 5.3 Live

6 GLOBAL RIFT VALLEY FEVER VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Cattle
• 6.3 Goats
• 6.4 People
• 6.5 Sheep
• 6.6 Other

7 GLOBAL RIFT VALLEY FEVER VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East

8 GLOBAL RIFT VALLEY FEVER VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Veterinary Serum and Vaccine Research Institute
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Onderstepoort Biological Products SOC Ltd
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Medgene Labs
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments

10 Appendix

• 10.1 Related Research